Targeting a specific protein to improve treatment for ovarian cancer
Targeting EGFL6 in Ovarian Cancer
This study is looking at a protein called EGFL6 in high-grade serous ovarian cancer to see if new treatments that block this protein can help improve cancer therapies and slow down tumor growth, and patients may have the chance to participate in trials to test these promising new options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11171048 on NIH RePORTER |
What this research studies
This research focuses on high-grade serous ovarian cancer, the most aggressive form of ovarian cancer, which has high mortality rates. The study investigates the role of a protein called EGFL6, which is found in tumor blood vessels and is linked to a suppressive immune environment in tumors. By developing and testing new antibodies that block EGFL6, the research aims to enhance the effectiveness of cancer therapies and reduce the growth of tumors. Patients may be involved in trials to assess the safety and efficacy of these new treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with high-grade serous ovarian cancer who may benefit from new therapeutic approaches.
Not a fit: Patients with other types of ovarian cancer or those who are not eligible for experimental therapies may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ovarian cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting angiogenesis in cancer treatment, but this specific approach targeting EGFL6 is novel.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Sood, Anil K — University of Tx Md Anderson Can Ctr
- Study coordinator: Sood, Anil K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.